The KIF2A Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the KIF2A gene in the HEK293T background. This product provides a heterogeneous pool of cells with targeted gene disruption, enabling loss-of-function studies without selection for a single clonal isolate. The polyclonal format retains genetic diversity, which can be advantageous for capturing a range of phenotypic effects and minimizing clonal artifacts in functional assays. Researchers can expect a robust reduction in KIF2A protein expression, confirmed by standard characterization methods such as western blotting, to facilitate investigations into KIF2A-dependent processes.
Hosted in the HEK293T cell line, this model leverages a well-established human embryonic kidney system that constitutively expresses the SV40 large T antigen. HEK293T cells are renowned for high transfection efficiency, rapid proliferation, and robust protein production, making them a workhorse for diverse applications including viral packaging, recombinant protein expression, and signal transduction studies. The epithelial-like morphology and straightforward culture conditions further enhance their utility for high-resolution microscopy and live-cell imaging. This genetic background provides an ideal platform for dissecting KIF2A function in mitosis and microtubule dynamics within a human cellular context.
KIF2A encodes a kinesin-13 family microtubule depolymerase that localizes to spindle poles and kinetochores, where it catalyzes the removal of tubulin subunits from microtubule ends to regulate spindle organization and chromosome movement. Its activity is tightly controlled throughout the cell cycle by upstream regulators including AURKA, AURKB, PLK1, and the CDK1/Cyclin B complex. KIF2A directly interacts with tubulin heterodimers, plus-end tracking proteins, and mitotic effectors such as KIF18A, KIFC1, Aurora B, and INCENP. It functions as a critical node in the mitotic spindle assembly checkpoint, influencing downstream targets like the chromosomal passenger complex, the anaphase-promoting complex/cyclosome (APC/C), and BubR1. Dysregulation of KIF2A leads to chromosome missegregation, contributing to genomic instability and pathologies such as cortical malformations, microcephaly, and tumorigenesis.
The HEK293T background enhances the utility of KIF2A knockout cells for mechanistic studies of mitosis and cell cycle control. The robust proliferation and tractable gene-expression machinery of these cells allow for acute perturbation and analysis of spindle checkpoint signaling. Loss of KIF2A in this system can induce measurable defects in microtubule depolymerization, leading to aberrant mitotic spindle morphology, prolonged mitosis, and chromosome alignment errors. These phenotypes can be readily quantified using immunofluorescence microscopy with tubulin and kinetochore markers, flow cytometry for DNA content, and time-lapse imaging of mitotic progression. By coupling the KIF2A knockout with the high transfection efficiency of HEK293T, researchers can introduce rescue constructs, fluorescent reporters, or pathway modulators to dissect the molecular circuitry of microtubule dynamics and chromosomal passenger complex function.
This polyclonal knockout cell population is suited for a broad range of investigative workflows including functional genomics screens, drug target validation, and cell-based assays for mitotic inhibitors. Representative applications encompass western blotting for KIF2A and downstream checkpoint proteins, immunofluorescence assessment of spindle morphology, flow-cytometric cell cycle profiling, and high-content live-cell imaging of chromosome segregation. Proliferation and migration assays can further bridge mitotic defects to tumorigenic potential. The model also supports studies into how KIF2A dysfunction contributes to neurodevelopmental disorders and cancer cell proliferation, offering a versatile resource for both basic and translational research. For further details or technical inquiries, please contact Ascent Research.
